Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMX-200 in FSGS patients receiving ARB
NCT05183646Phase 3Recruiting
- Sponsor
- Dimerix
- Start
- May 2022
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of repagermanium in focal segmental glomerulosclerosis (FSGS), sponsored by Dimerix. Started May 2022; status: recruiting.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05183646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183646.